Please be aware that the information provided is a summary of select releases made to the ASX, as evaluated and interpreted by ASX Briefs. It is important to thoroughly read the entire original release before forming an opinion, rather than relying solely on the brief overview presented here. ASX Briefs is not associated with the ASX. ASX Briefs is an experimental AI project incorporating chatGPT, and as such, does not guarantee the accuracy of the information provided.
Microba Life Sciences Limited has signed a commercial contract with Sonic Healthcare Limited, through its subsidiary Douglass Hanly Moir Pathology Pty Ltd, to distribute Microba's MetaPanel™ infectious disease test in Australia.
This agreement is the first between Microba and Sonic Healthcare since Sonic's strategic investment of $17.8 million into Microba on 29 November 2022.
Sonic Healthcare now has exclusive distribution rights to provide the MetaPanel™ test across Australia through its Pathology network, marking the completion of the first of their commercial distribution agreements.
Microba Life Sciences Limited announces the successful dosing of the first participants in the Phase I Clinical Trial of its potential new treatment for ulcerative colitis, a drug candidate known as MAP 315.
The trial, which is a randomised, double-blind, placebo-controlled study on 32 healthy adults, is being conducted by Nucleus Network in Melbourne, Australia and is aligned with FDA pre-IND engagement.
Results from the trial, featuring two cohorts of 16 participants each receiving MAP 315 or a matching placebo for 14 consecutive days, are expected to be available by December 2023.
Microba has signed agreements with SYNLAB International GmbH affiliates Referans M-B Saglik Labopratuvar and SYNLAB Czech s.r.o. to distribute its testing technology into Türkiye and Czech Republic respectively.
The agreements provide SYNLAB affiliate organisations with non-exclusive distribution rights out to 31 December 2028.
Additional affiliate country agreements are expected to be completed in the near future.
Microba Life Sciences Limited has signed a distribution agreement with Luminary Health Centers Inc. to distribute a microbiome test powered by Microba’s testing technology to consumers in the United States.
The agreement provides non-exclusive distribution rights out to 2027 and the initial 12 month phase has a value of USD $458,000 to Microba.
This partnership expands Microba's distribution base to deliver its testing technology to clinicians, patients and consumers.